Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT01220297 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Hematologic Diseases
Acute-graft-versus-host Disease
Leukemia
Non-Hodgkin Lymphoma (NHL)
Hodgkin Lymphoma

Interventions

DRUG: Sirolimus
DRUG: Mycophenolate mofetil (MMF)
DRUG: Carmustine
DRUG: Etoposide
DRUG: Cyclophosphamide (Cyclo, CY)
DRUG: FTBI

Sponsor

Stanford University